News Radiopharm Theranostics Limited

Equities

RAD

AU0000181851

Market Closed - Australian S.E. Other stock markets 09:23:38 10/05/2024 am IST			5-day change	1st Jan Change
0.04 ^AUD	+2.56%		0.00%	-45.95%

08/05	Radiopharm Theranostics to be Featured in Healthcare Events Hosted by B. Riley Securities	MT
29/02	Radiopharm Theranostics Doses First Patient in Pancreatic Cancer Imaging Study	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Radiopharm Theranostics to be Featured in Healthcare Events Hosted by B. Riley Securities	08/05	MT
Radiopharm Theranostics Doses First Patient in Pancreatic Cancer Imaging Study	29/02	MT
Radiopharm Theranostics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	29/02	CI
Radiopharm Theranostics Receives AU$1.9 Million Advance on R&D Tax Rebate	21/02	MT
Radiopharm Secures Investment from US-based Lind Partners; Shares Decline 6%	06/02	MT
Radiopharm Theranostics Raises AU$1.7 Million Via Shortfall Placement	24/01	MT
Radiopharm Theranostics Secures Ethics Approval for Second Lung Cancer Trial Site	27/12	MT
Radiopharm Theranostics to Start Phase One Lung Cancer Therapy Trial	26/12	MT
Radiopharm Theranostics Raises AU$2.1 Million Via Entitlement Offer	08/12	MT
28,046,696 Options of Radiopharm Theranostics Limited are subject to a Lock-Up Agreement Ending on 25-NOV-2023.	25/11	CI
100,000,000 Ordinary Shares of Radiopharm Theranostics Limited are subject to a Lock-Up Agreement Ending on 25-NOV-2023.	25/11	CI
Radiopharm Theranostics Secures AU$5 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 4%	21/11	MT
Radiopharm Theranostics Secures US FDA Approval for Phase 1 Pancreatic Cancer Diagnostic Trial	17/23/17	MT
RAD receives approval for Phase 1 therapeutic study of PDL1-nanobody in Non-Small Cell Lung Cancer	09/23/09	AQ
Radiopharm Theranostics Secures Ethics Approval for Lung Cancer Trial; Shares Rise 4%	09/23/09	MT
Radiopharm Theranostics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/23/31	CI
Radiopharm Theranostics Expands Supply Agreement With TerThera for Terbium-161 Isotope Use in Prostate Cancer	24/23/24	AQ
Radiopharm welcomes positive guidance from FDA to advance Pivalate	31/23/31	AQ
Radiopharm Theranostics Secures US FDA Guidance for Clinical Trial of Imaging Drug in Brain Metastasis	29/23/29	MT
Radiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancer	09/23/09	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Radiopharm Theranostics Limited

Equities

RAD

AU0000181851

Summary

Filters